مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

293
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

154
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

1

Information Journal Paper

Title

Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®

Pages

  635-640

Abstract

 Factor XIII deficiency (FXIIID) is an extremely rare hemorrhagic disorder with a prevalence of 1/3-5 million. Management of disease is performed by fresh frozen plasma (FFP), Cryoprecipitate (CP) or FXIII concentrate (Fibrogammin P®; ). Our objective was to assess Safety and Effectiveness of Fibrogammin P®; in patients with FXIIID. For this purpose we designed this long-term follow up study on a large group of patients with FXIIID. This prospective study was conducted on 213 patients with FXIIID since 2009 to 2013. Administrated dose for Fibrogammin P®; according to clinical situations of patients ranged from 10 to 26 IU/kg every 4-6 weeks. All patients in 6-month intervals were checked for human immunodeficiency virus (HIV), hepatitis A, B and C viruses (HAV, HBV, HCV). Twelve percent of participants had at least one ICH episode until 2008 but after administration of Fibrogammin P®; did not have any major bleeding or episode of ICH, except in one patient. We also had 7 females with recurrent miscarriage that were managed successfully with a dose of 10 to 26 IU/kg every 4-6 weeks. This dose also was quite successful in management of major and minor surgery. None of the participants showed allergic reaction during treatment. A total of 7155450 IU of Fibrogammin P®; were infused but nobody was positive for HIV, HAV, HBV, and HCV. We found that Fibrogammin P®; is a safe and effective therapeutic choice in management of FXIIID.

Cites

References

  • No record.

    • Cite

    APA: Copy

    NADERI, MAJID, KARIMI, MEHRAN, Hosseini, Maryam Sadat, MORADI, ESHAGH, SHAMSIZADEH, MORTEZA, & DORGALALEH, AKBAR. (2016). Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), 15(2), 635-640. SID. https://sid.ir/paper/288638/en

    Vancouver: Copy

    NADERI MAJID, KARIMI MEHRAN, Hosseini Maryam Sadat, MORADI ESHAGH, SHAMSIZADEH MORTEZA, DORGALALEH AKBAR. Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR)[Internet]. 2016;15(2):635-640. Available from: https://sid.ir/paper/288638/en

    IEEE: Copy

    MAJID NADERI, MEHRAN KARIMI, Maryam Sadat Hosseini, ESHAGH MORADI, MORTEZA SHAMSIZADEH, and AKBAR DORGALALEH, “Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®,” IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), vol. 15, no. 2, pp. 635–640, 2016, [Online]. Available: https://sid.ir/paper/288638/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button